Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All nigella sativa studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial

Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, after 14 day foll.. 81% Improvement Relative Risk Mortality, in hospital 89% ICU admission 87% Hospitalization time 35% Nigella Sativa  Vaziri et al.  LATE TREATMENT  RCT Is late treatment with nigella sativa + combined treatments beneficial for COVID-19? RCT 179 patients in Iran (April - December 2020) Lower mortality (p=0.03) and ICU admission (p=0.0019) c19early.org Vaziri et al., Heliyon, March 2024 Favorsnigella sativa Favorscontrol 0 0.5 1 1.5 2+
12th treatment shown to reduce risk in January 2021
 
*, now with p = 0.00016 from 14 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 102 treatments. c19early.org
RCT 179 hospitalized COVID-19 patients showing lower mortality, ICU admission, and hospitalization duration with colchicine plus phenolic monoterpenes compared to standard care alone. The intervention group received 0.8 mg/day colchicine and 45 mg/day phenolic monoterpenes extracted from nigella sativa and Trachyspermum ammi in addition to standard care (lopinavir/ritonavir). No serious side effects were reported. Baseline SpO2 was significantly lower in the control group, although there was no significant difference in severity according to NIH guidelines.
Study covers nigella sativa and colchicine.
risk of death, 81.2% lower, RR 0.19, p = 0.03, treatment 2 of 108 (1.9%), control 7 of 71 (9.9%), NNT 12, after 14 day followup.
risk of death, 89.0% lower, RR 0.11, p = 0.02, treatment 1 of 108 (0.9%), control 6 of 71 (8.5%), NNT 13, in hospital.
risk of ICU admission, 86.9% lower, RR 0.13, p = 0.002, treatment 2 of 108 (1.9%), control 10 of 71 (14.1%), NNT 8.2.
hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment mean 4.17 (±1.34) n=108, control mean 6.39 (±2.59) n=71.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Vaziri et al., 6 Mar 2024, Randomized Controlled Trial, Iran, peer-reviewed, mean age 54.2, 11 authors, study period April 2020 - December 2020, this trial uses multiple treatments in the treatment arm (combined with colchicine and phenolic monoterpenes from nigella sativa and Trachyspermum ammi) - results of individual treatments may vary, trial NCT04392141 (history). Contact: amostafaie@kums.ac.ir.
This PaperNigella SativaAll
{ 'indexed': {'date-parts': [[2024, 3, 7]], 'date-time': '2024-03-07T00:33:10Z', 'timestamp': 1709771590804}, 'reference-count': 14, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T00:00:00Z', 'timestamp': 1709251200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2024, 2, 28]], 'date-time': '2024-02-28T00:00:00Z', 'timestamp': 1709078400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': { 'domain': ['cell.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2024, 3]]}, 'DOI': '10.1016/j.heliyon.2024.e27373', 'type': 'journal-article', 'created': {'date-parts': [[2024, 3, 6]], 'date-time': '2024-03-06T08:28:28Z', 'timestamp': 1709713708000}, 'page': 'e27373', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential ' 'treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial', 'prefix': '10.1016', 'author': [ {'given': 'Siavash', 'family': 'Vaziri', 'sequence': 'first', 'affiliation': []}, {'given': 'Alireza', 'family': 'Janbakhsh', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Mohammad Hossein', 'family': 'Zamanian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yadollah', 'family': 'Shakiba', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shayan', 'family': 'Mostafaei', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Amir Hossein', 'family': 'Norooznezhad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kamran', 'family': 'Mansouri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmad', 'family': 'Bagheri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Farhad', 'family': 'Abdali', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kavyan', 'family': 'Fatahpour', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Mostafaie', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.heliyon.2024.e27373_bib1', 'doi-asserted-by': 'crossref', 'first-page': '834', 'DOI': '10.4269/ajtmh.20-0512', 'article-title': 'Primary symptoms, comorbidities, and outcomes of 431 hospitalized ' 'patients with confirmative RT-PCR results for COVID-19', 'volume': '103', 'author': 'Norooznezhad', 'year': '2020', 'journal-title': 'Am. J. Trop. Med. Hyg.'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib2', 'doi-asserted-by': 'crossref', 'first-page': '347', 'DOI': '10.1016/j.arcmed.2020.03.015', 'article-title': 'Inappropriate antibiotic consumption as a possible cause of ' 'inflammatory storm and septic shock in patients diagnosed with ' 'coronavirus-19 disease (COVID-19)', 'volume': '51', 'author': 'Hantoushzadeh', 'year': '2020', 'journal-title': 'Arch. Med. Res.'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib4', 'doi-asserted-by': 'crossref', 'first-page': '664', 'DOI': '10.1002/jmv.26525', 'article-title': 'Changes of leukocytes, neutrophils, and lymphocytes count and dependent ' 'variables in pregnant women with coronavirus disease 2019 (COVID-19) ' 'before and after cesarean delivery', 'volume': '2', 'author': 'Norooznezhad', 'year': '2021', 'journal-title': 'J. Med. Virol.'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1583', 'DOI': '10.3390/jcm9051583', 'article-title': 'Herbal medicine for the treatment of coronavirus disease 2019 ' '(COVID-19): a systematic review and meta-analysis of randomized ' 'controlled trials', 'volume': '9', 'author': 'Ang', 'year': '2020', 'journal-title': 'J. Clin. Med.'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib6', 'series-title': 'Definitions of Symptoms for Reportable Illnesses', 'year': '2020'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib8', 'series-title': 'Management of Persons with COVID-19', 'year': '2020'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib9', 'article-title': 'Effect of colchicine vs standard care on cardiac and inflammatory ' 'biomarkers and clinical outcomes in patients hospitalized with ' 'coronavirus disease 2019: the GRECCO-19 randomized clinical trial', 'volume': '3', 'author': 'Deftereos', 'year': '2020', 'journal-title': 'JAMA New Open'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib10', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/rmdopen-2020-001455', 'article-title': 'Beneficial effects of colchicine for moderate to severe COVID-19: a ' 'randomised, double-blinded, placebo-controlled clinical trial', 'volume': '7', 'author': 'Lopes', 'year': '2021', 'journal-title': 'RMD Open'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib11', 'doi-asserted-by': 'crossref', 'first-page': '703', 'DOI': '10.1186/s13063-020-04647-x', 'article-title': 'Nigella sativa supplementation to treat symptomatic mild COVID-19: a ' 'structured summary of a protocol for a randomised, controlled, clinical ' 'trial', 'volume': '21', 'author': 'Koshak', 'year': '2020', 'journal-title': 'Trials'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib12', 'doi-asserted-by': 'crossref', 'first-page': '341', 'DOI': '10.1016/j.semarthrit.2015.06.013', 'article-title': 'Colchicine--Update on mechanisms of action and therapeutic uses', 'volume': '45', 'author': 'Leung', 'year': '2015', 'journal-title': 'Semin. Arthritis Rheum.'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib13', 'doi-asserted-by': 'crossref', 'first-page': '52', 'DOI': '10.2174/1871529X18666180212114816', 'article-title': 'Immunomodulatory and anti-inflammatory effects of thymoquinone', 'volume': '18', 'author': 'Shaterzadeh-Yazdi', 'year': '2018', 'journal-title': 'Cardiovasc. Hematol. Disord.: Drug Targets'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib14', 'doi-asserted-by': 'crossref', 'first-page': '897', 'DOI': '10.3390/antiox9090897', 'article-title': 'Implications of oxidative stress and potential role of mitochondrial ' 'dysfunction in COVID-19: therapeutic effects of vitamin D', 'volume': '9', 'author': 'de Las Heras', 'year': '2020', 'journal-title': 'Antioxidants'}, { 'key': '10.1016/j.heliyon.2024.e27373_bib15', 'doi-asserted-by': 'crossref', 'first-page': '3038', 'DOI': '10.1093/eurheartj/ehaa623', 'article-title': 'COVID-19 is, in the end, an endothelial disease', 'volume': '41', 'author': 'Libby', 'year': '2020', 'journal-title': 'Eur. Heart J.'}], 'container-title': 'Heliyon', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2405844024034042?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2405844024034042?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2024, 3, 6]], 'date-time': '2024-03-06T08:28:35Z', 'timestamp': 1709713715000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2405844024034042'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 3]]}, 'references-count': 14, 'alternative-id': ['S2405844024034042'], 'URL': 'http://dx.doi.org/10.1016/j.heliyon.2024.e27373', 'relation': {}, 'ISSN': ['2405-8440'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Heliyon', 'published': {'date-parts': [[2024, 3]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a ' 'potential treatment for patients diagnosed with COVID-19: A randomized ' 'controlled parallel clinical trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Heliyon', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.heliyon.2024.e27373', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2024 The Authors. Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': 'e27373'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit